Preliminary findings show arthritis drug to be effective in treating sickest COVID-19 patients

COVID-19ICU
Written By Guest User
ICU.jpg

Emerging evidence from the REMAP-CAP trial has shown an arthritis drug to be effective in treating the sickest COVID-19 patients.

New Zealand’s participation in the study is coordinated by the Medical Research Institute of New Zealand Intensive Care team, and funded by the Health Research Council of New Zealand and the Ministry of Health.

Read the HRC media release here: https://hrc.govt.nz/news-and-events/preliminary-findings-show-arthritis-drug-be-effective-treating-sickest-covid-19

Guest User
Previous

"Swimming between the flags" - prescribing oxygen safely for patients with COPD

Next

Using comics and curiosity to drive pandemic research on a national scale